4
Views
1
CrossRef citations to date
0
Altmetric
Drug Profile

Transdermal oxybutynin: topical therapy for overactive bladder syndrome

Pages 175-179 | Published online: 10 Jan 2014
 

Abstract

Overactive bladder syndrome is a prevalent condition comprising urinary urgency and frequency and, in approximately a third of sufferers, urinary incontinence, which causes considerable morbidity in the population. The efficacy of management through behavioral and lifestyle measures is limited, and has led to the development of a range of pharmacological agents for treatment. These are mainly antimuscarinic compounds which, although effective, have limited tolerability due to their side-effect profile. Alternative delivery mechanisms have been explored with the aim of avoiding these side effects. The transdermal route of administering oxybutynin has been found to be efficacious in terms of treating the condition, and avoids the common side effects of dry mouth and constipation. However, its use can be limited by local skin reactions at the application site.

Financial & competing interests disclosure

The author has received research monies, fees for speaking from UCB-pharma, the marketing company for oxybutynin TDS in the UK, Pfizer, Astellas, Ardana and Boehringer Ingelheim. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.